Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicentre Open Label Trial Evaluating the Efficacy and Safety of the Liposomal Doxorubicin (Myocet®) and Docetaxel (Taxotere®) Combination as First-line Treatment of Patients With Metastatic HER2/Neu Negative Breast Cancer

NCT00377559 is registered in ClinicalTrials.gov with Catharina Ziekenhuis Eindhoven as lead sponsor.

NCT NCT00377559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00377559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicentre Open Label Trial Evaluating the Efficacy and Safety of the Liposomal Doxorubicin (Myocet®) and Docetaxel (Taxotere®) Combination as First-line Treatment of Patients With Metastatic HER2/Neu Negative Breast Cancer
Lead sponsor
Catharina Ziekenhuis Eindhoven
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2006
Completion date
July 31, 2011
Enrollment
70 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, neoplasm metastasis